Premium
Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy
Author(s) -
Bauer Larry A,
Stenwall Mark,
Horn John R,
Davis Robin,
Opheim Kent,
Greene Leon
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.169
Subject(s) - diltiazem , verapamil , nifedipine , indocyanine green , pharmacology , drug interaction , medicine , pharmacokinetics , chemistry , calcium , surgery
Ten healthy subjects received oral antipyrine and intravenous indocyanine green (ICG) alone and after 5 days of oral nifedipine, diltiazem, and verapamil. Antipyrine clearance decreased during verapamil (range 4% to 26%) and diltiazem (6% to 24%) therapy (P < 0.001) but did not change during nifedipine treatment. Antipyrine t 1/2 also increased during verapamil and diltiazem treatment (P < 0.001). ICG clearance did not change during diltiazem therapy but increased during dosing with nifedipine and verapamil (P < 0.05). Estimated liver blood flow (derived from ICG clearance and hematocrit) also increased during verapamil (mean 33%) and nifedipine (mean 27%) treatment (P < 0.05). Drug interactions with other liver‐metabolized drugs may occur during therapy with these calcium antagonists. Nifedipine appears to increase liver blood flow whereas diltiazem inhibits oxidative drug metabolism. Drug interactions with verapamil could involve both mechanisms. Clinical Pharmacology and Therapeutics (1986) 40, 239–242; doi: 10.1038/clpt.1986.169